Journal of the Chinese Medical Association : JCMA · 2025
Real-world experience in treatment outcome and genomic insights for metastatic prostate neuroendocrine carcinoma.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Lai Jiun-I, Peng Yu-Ching, Chang Peter Mu-Hsin, Chang Yen-Hwa, Chung Hsiao-Jen, Huang Yi-Hsiu, Lin Tzu-Ping, Huang William J, Wei Tzu-Chun, Huang Tzu-Hao, Yen Chueh-Chuan
Аннотация
BACKGROUND: Neuroendocrine prostate cancer (NEPC) (de novo or treatment-related [t-NEPC]) is a rare and deadly variant of prostate cancer. While de novo NEPC is rare, t-NEPC occurs more frequently in patients with castration-refractory prostate cancer. Owing to the rarity of NEPC, no standard treatment has been established, and the outcomes are generally unsatisfactory.
METHODS: This study retrospectively reviewed NEPC cases at Taipei Veterans General Hospital between 2018 and 2023. Clinical outcomes, treatment modalities, and related genomic profiles were recorded. We also performed a literature review of case series reporting the outcomes of chemotherapeutic regimens for NEPC.
RESULTS: From 2158 cases of prostate cancer cases diagnosed during the study period, only 7 had pathologically proven NEPC (0.3%), and the median overall survival was 364 days. Three patients who underwent multigene panel sequencing had mutations in RB1, and delta-like ligand 3 (DLL3) immunohistochemical staining showed a positivity rate of 50%. We performed a literature review on chemotherapy outcomes in patients with NEPC. In six studies with 104 patients, etoposide + platinum treatment was most commonly used. The progression-free survival (PFS) and overall survival ranged from 3.4 to 9.3 and 8.4 to 22.4 months, respectively. The response rates ranged from 44% to 69.2%. These studies were consistent with a dismal overall survival rate, despite a high response rate to the initial chemotherapy regimen.
CONCLUSION: Our study reported poor outcomes with chemotherapy, with a high frequency of retinoblastoma protein (RB) loss and DLL3 positivity. Further clinical developments targeting DLL3 are warranted.
METHODS: This study retrospectively reviewed NEPC cases at Taipei Veterans General Hospital between 2018 and 2023. Clinical outcomes, treatment modalities, and related genomic profiles were recorded. We also performed a literature review of case series reporting the outcomes of chemotherapeutic regimens for NEPC.
RESULTS: From 2158 cases of prostate cancer cases diagnosed during the study period, only 7 had pathologically proven NEPC (0.3%), and the median overall survival was 364 days. Three patients who underwent multigene panel sequencing had mutations in RB1, and delta-like ligand 3 (DLL3) immunohistochemical staining showed a positivity rate of 50%. We performed a literature review on chemotherapy outcomes in patients with NEPC. In six studies with 104 patients, etoposide + platinum treatment was most commonly used. The progression-free survival (PFS) and overall survival ranged from 3.4 to 9.3 and 8.4 to 22.4 months, respectively. The response rates ranged from 44% to 69.2%. These studies were consistent with a dismal overall survival rate, despite a high response rate to the initial chemotherapy regimen.
CONCLUSION: Our study reported poor outcomes with chemotherapy, with a high frequency of retinoblastoma protein (RB) loss and DLL3 positivity. Further clinical developments targeting DLL3 are warranted.